Search Results for 'Nrti'

Nrti published presentations and documents on DocSlides.

DOR + 2 NRTIs vs. DRV + RTV + 2 NRTIs
DOR + 2 NRTIs vs. DRV + RTV + 2 NRTIs
by maximus
DRIVE FORWARD. Doravirine. + 2 NRTIs vs. Darunavi...
Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs
Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs
by roxanne
FLAMINGO. Dolutegravir + 2 NRTIs versus Darunavir ...
LPV-RTV + 3TC vs. LPV-RTV + 2 NRTIs in
LPV-RTV + 3TC vs. LPV-RTV + 2 NRTIs in
by lucy
Virologically. Suppressed. OLE Trial. LPV-RTV + ....
Switching the NRTI Backbone to Tenofovir DF-Emtricitabine
Switching the NRTI Backbone to Tenofovir DF-Emtricitabine
by reese
TOTEM. Switching the NRTI Backbone to Tenofovir DF...
Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine
Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine
by kylie
STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine ...
A nti- R etroviral  T herapy Basics
A nti- R etroviral T herapy Basics
by caroline
E Duke. https://www.hiv.uw.edu/page/treatment/drug...
DTG vs LPV/r (DAWNING): Efficacy
DTG vs LPV/r (DAWNING): Efficacy
by winnie
by Baseline NRTI Resistance . and Second-Line NRTI...
Optimizing HIV treatment
Optimizing HIV treatment
by anderson
Professor Francois Venter. Ezintsha, University of...
Lopinavir -RTV  +  NVP  +
Lopinavir -RTV + NVP +
by thomas
2 NRTIs in Treatment-Experienced. M97-765 Trial. L...
HIV Treatment 101 C. Ryan Tomlin, Pharm.D., BCPS, AAHIVP
HIV Treatment 101 C. Ryan Tomlin, Pharm.D., BCPS, AAHIVP
by Powerpixel
Clinical Pharmacist – HIV Medicine. Outline. Wha...
Switch a ATV/r   3TC Estudio ATLAS-M
Switch a ATV/r 3TC Estudio ATLAS-M
by pamella-moone
ATV/r 300/100 mg QD 3TC 300 mg QD. N = 133. N =...
Superior Efficacy of Dolutegravir (DTG) Plus
Superior Efficacy of Dolutegravir (DTG) Plus
by celsa-spraggs
2 Nucleoside Reverse Transcriptase Inhibitors (NR...
ART Resistance and  Second Line Regimens
ART Resistance and Second Line Regimens
by calandra-battersby
Learning Objectives. Understand when to switch to...
Management of NRTI Resistance
Management of NRTI Resistance
by giovanna-bartolotta
David Spach, MD. Principal . Investigator, NW AET...
Comparison of NNRTI vs PI/r
Comparison of NNRTI vs PI/r
by alexa-scheidler
EFV vs LPV/r vs EFV + LPV/r . A5142. Mexican. . ...
Comparison of INSTI vs PI
Comparison of INSTI vs PI
by conchita-marotz
FLAMINGO. GS-236-0103. ACTG . A5257. WAVES. . De...
Switch PI/R to ETR Etraswitch
Switch PI/R to ETR Etraswitch
by dustin869
Etraswitch. . Study. : Switch PI/r to ETR. Contin...
NRTI-sparing SPARTAN PROGRESS
NRTI-sparing SPARTAN PROGRESS
by shepard237
RADAR. NEAT001/ANRS 14. 3 . A4001078. VEMAN. MODER...
Dolutegravir ( Tivicay )
Dolutegravir ( Tivicay )
by brown
Prepared by:. Brian R. Wood, MD. David H. Spach, M...
Dolutegravir   vs.  Raltegravir
Dolutegravir vs. Raltegravir
by zoe
SPRING-2 Study. Dolutegravir. versus Raltegravir....
Switching Antiretroviral Therapy (ART) in Your African American Patients: When and How
Switching Antiretroviral Therapy (ART) in Your African American Patients: When and How
by taylor
Supported by an educational grant from Gilead Scie...
What’s new in the 2019 WHO Guidelines:
What’s new in the 2019 WHO Guidelines:
by elina
Dolutegravir based regimens in first- ad second-li...
Zidovudine Retrovir AZT  Class  Zidovudine is a thymidine analog
Zidovudine Retrovir AZT Class Zidovudine is a thymidine analog
by mackenzie
Disease state based dosing: �Clcr 10 mL/min...
Meg  Doherty MD MPH PhD 23 July 2018
Meg Doherty MD MPH PhD 23 July 2018
by jordyn
WHO HQ. The role of DTG based regimens in first- a...
Switch to LPV/ r  + 3TC OLE
Switch to LPV/ r + 3TC OLE
by susan2
Study. LPV/. r. bid + 3TC or FTC . qd. + NRTI. N ...
CROI 2019:  ARV for Prevention and Treatment, HIV Pathogenesis, and Cure
CROI 2019: ARV for Prevention and Treatment, HIV Pathogenesis, and Cure
by brown
Joseph J. Eron, Jr, MD. Professor of Medicine. Uni...
Joel E. Gallant, MD, MPH
Joel E. Gallant, MD, MPH
by mastervisa
Medical Director, Specialty . Services. Southwest ...
ART in Women and  Contraception: InSTIs
ART in Women and Contraception: InSTIs
by olivia-moreira
ART in Women and Contraception: InSTIs , Comorbi...
Phase 2 of new ARVs Fostemsavir
Phase 2 of new ARVs Fostemsavir
by conchita-marotz
, . prodrug. of . temsavir. . (attachment inhib...
Ellen G. Chadwick, MD Professor of Pediatrics
Ellen G. Chadwick, MD Professor of Pediatrics
by mitsue-stanley
Northwestern University Feinberg School of Medici...
Essentials for Optimal Care of HIV Patients
Essentials for Optimal Care of HIV Patients
by marina-yarberry
Evidence-Based Approaches. Simply Speaking. ®. ...
Opportunities for the use of new ARVs for infants, children and adolescents and updated guidance on
Opportunities for the use of new ARVs for infants, children and adolescents and updated guidance on
by myesha-ticknor
Martina Penazzato MD, PhD. Paediatric lead, HIV D...
Modifying Therapy in the Treatment-experienced Patient:
Modifying Therapy in the Treatment-experienced Patient:
by yoshiko-marsland
When should it be done?. Professor of Medicine. U...
Updated WHO Treatment Guidelines  &
Updated WHO Treatment Guidelines &
by mitsue-stanley
Data . from other . cohorts and . regions to guid...
HIV Pharmacotherapy Focused Update
HIV Pharmacotherapy Focused Update
by yoshiko-marsland
Drew Lambert, . PharmD. lambertd@husson.edu. Huss...
Advances and Challenges in HIV Antiretroviral Therapy
Advances and Challenges in HIV Antiretroviral Therapy
by stefany-barnette
Camille Angle, Meagan Bardan, Hanna Schimjawicz a...
Antiretroviral Updates:
Antiretroviral Updates:
by tatyana-admore
New Treatments for HIV. C. Ryan Tomlin, . Pharm.D...
Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine
Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine
by luanne-stotts
Chief, Division of Infectious Diseases. Weill Med...
NRTI-sparing
NRTI-sparing
by liane-varnes
SPARTAN. PROGRESS. RADAR. NEAT001/ANRS 14. 3. A40...
Comparison of NRTI combinations
Comparison of NRTI combinations
by tawny-fly
ZDV/3TC . vs. TDF + FTC. Study 934. ABC/3TC . vs...